Clinical Trial, BeNeLux

Prosensa Publishes DMD study results in NEJM

19.02.2008

Prosensa NV and researchers from Leiden University Medical Center (LUMC) under Prosensa's scientific advisor Prof. Gertjan van Ommen have published results from a Phase I clinical study with the 2-’O-methyl antisense compound PRO051 in four children (aged 10-13) with Duchenne Muscular Dystrophy (DMD) (N Engl J Med. 357(26):2677-86). Intramuscular injection of a single 80 mg shot of the compound, which is able to correct the open reading frame of the DMD gene by exon skipping and thus to restore dystrophin expression, was not associated with clinical adverse reactions, according to Prosensa. Additionally, PRO051 restored dystrophin expression in the treated muscle fibers of all four patients, who had been selected on the basis of their mutational status, muscle condition, and positive exon-skipping response to PRO051 in vitro. The compound will be suitable for 13% of all DMD patients (DMD incidence

1: 3,500), because it can treat a cluster of DMD mutations.

Miscellaneous

16.03.2007

After stock markets’ worldwide strong start into 2007, last week of February saw the beginning of a correction phase. By 15 February, the WestLB EU Biotech index went up by 4.2%, again outperforming both the Nasdaq Biotech index...

Miscellaneous

16.03.2007

Strasbourg – The European Science Foundation (ESF) launched a new call in March for its funding program EuroBio­Fund (www.esf.org/eurobiofund/eoi), set up in 2006 to identify future grand challenges in life science research,...

Miscellaneous

16.03.2007

Brussels – The number of cancer cases in Europe is rising. According to a new study by the International Cancer Center (IACR), a WHO division based in Lyon (France), 3.2 million new cases were dia­gnosed in 2006, 300,000 more...

Miscellaneous

16.03.2007

“The IMI does not want to develop new medicines or new vaccines”, said EC representative Hoeveler during an IMI information meeting in Germany, which was organized in February by members from the Baltic See network ScanBalt. The...

Clinical Trial

15.03.2007

Novo Nordisk A/S (Bagsværd, Denmark) will not seek regulatory approval for its human recombinant activated coagulation factor VII NovoSeven (Eptacog alfa) as a treatment for intra-cerebral haemorrhage, the most severe...

Politics / Law

15.03.2007

Three countries have pooled their expertise in the field of plant genomics in a transnational funding initiative that is unique within the European Union. The cooperation between the plant genome research programmes in Germany...

Clinical Trial, Germany

30.01.2007

Affimed Therapeutics AG (Heidelberg, Germany) announced that preclinical proof of concept has been established for Anti GPIIb/IIa, its anti-thrombosis product candidate as a treatment for cardiovascular disease in conjunction...

Clinical Trial

30.01.2007

Crucell N.V. (Leiden, The Netherlands) has announced two Phase I trials. One is a dose-escalation study with a heteromeric human monoclonal antibody (mAb) for the post-exposure prophylaxis (PEP) of rabies, which will involve 60...

Clinical Trial

30.01.2007

Serono S.A. (Geneva, Switzerland) and its US partner ZymoGenetics Inc. (Seattle) have started a proof-of-concept Phase II study with its protein drug atacicept (TACI-Ig) in 320 patients with rheumatoid arthritis (RA). The...

Displaying results 811 to 820 out of 1982

< Previous 811-820 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/81/article/prosensa-publishes-dmd-study-results-in-nejm.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events